Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes
Background: Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its effect on postoperative outcomes following robotic-assisted tho...
Gespeichert in:
Veröffentlicht in: | Cancers 2024-11, Vol.16 (23), p.3938 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 23 |
container_start_page | 3938 |
container_title | Cancers |
container_volume | 16 |
creator | Serratosa, Inés Déniz, Carlos Moreno, Camilo Macia, Iván Rivas, Francisco Muñoz, Anna Paradela, Marina Nadal, Ernest Mosteiro, Miguel Padrones, Susana García, Marta Rodríguez-Martos, Tania Marcè, Judith Ojanguren, Amaia |
description | Background: Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its effect on postoperative outcomes following robotic-assisted thoracic surgery (RATS) is not fully characterized. Objective: This study aimed to evaluate the impact of neoadjuvant therapy on postoperative outcomes in patients undergoing RATS for NSCLC, focusing on operative time, conversion rates to open surgery, and postoperative complications. Methods: A retrospective cohort analysis was performed on patients who underwent RATS for NSCLC between February 2019 and August 2024. Propensity score matching was utilized to balance preoperative characteristics between the groups. The primary outcomes compared were operative time, conversion rates to open surgery, and postoperative complications, with statistical significance defined as p < 0.05. Results: A total of 253 patients were included in the analysis, of whom 23 received neoadjuvant therapy (either chemotherapy or chemoimmunotherapy) and 230 did not. The neoadjuvant group had significantly longer operative times (250 min vs. 221 min, p = 0.001) but there were no significant differences in conversion rates to open surgery (8.7% vs. 3.9%, p = 0.5). However, the neoadjuvant group showed a higher incidence of prolonged air leaks (>5 days) (39.13% vs. 35.21%, p < 0.001). Other parameters, such as hospital stay and chest drainage duration, showed no statistically significant differences between the groups (p = 0.860 and p = 0.760, respectively). Conclusions: These findings support the feasibility of robotic-assisted thoracic surgery following neoadjuvant therapy in NSCLC, suggesting that this approach may be safely integrated into clinical practice for selected patients. Further studies are needed to define patient selection criteria and optimize postoperative management, potentially guiding personalized treatment strategies in complex cases. |
doi_str_mv | 10.3390/cancers16233938 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3143902809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3143902809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1098-1e06be357f9b8cd42e4c265ec193f7b009d7efb36a9209c9701d65cf1f8137283</originalsourceid><addsrcrecordid>eNpdkM1Lw0AQxRdRsNSevS54ju5Hupv1JqV-QLGgFY9hs5m0W5Js3d0U89-b2h7EuczM4zFv-CF0Tckt54rcGd0a8IEKNqw8O0MjRiRLhFDp-Z_5Ek1C2JKhOKdSyBHavILT5bbb6zbi1Qa83vXYtvjNFS5agxddu8bvnV-D7-_xvIa9jvYkWaNrPHPNroZvG3v8aePGdfFX8q6x4WBcdtG4BsIVuqh0HWBy6mP08ThfzZ6TxfLpZfawSAwlKksoEFEAn8pKFZkpUwapYWIKhipeyYIQVUqoCi60YkQZJQktxdRUtMoolyzjY3RzvDu88NVBiPnWdb4dInNO04EVy4gaXHdHl_EuBA9VvvO20b7PKckPRPN_RPkP_XVrtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3143902809</pqid></control><display><type>article</type><title>Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Serratosa, Inés ; Déniz, Carlos ; Moreno, Camilo ; Macia, Iván ; Rivas, Francisco ; Muñoz, Anna ; Paradela, Marina ; Nadal, Ernest ; Mosteiro, Miguel ; Padrones, Susana ; García, Marta ; Rodríguez-Martos, Tania ; Marcè, Judith ; Ojanguren, Amaia</creator><creatorcontrib>Serratosa, Inés ; Déniz, Carlos ; Moreno, Camilo ; Macia, Iván ; Rivas, Francisco ; Muñoz, Anna ; Paradela, Marina ; Nadal, Ernest ; Mosteiro, Miguel ; Padrones, Susana ; García, Marta ; Rodríguez-Martos, Tania ; Marcè, Judith ; Ojanguren, Amaia</creatorcontrib><description>Background: Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its effect on postoperative outcomes following robotic-assisted thoracic surgery (RATS) is not fully characterized. Objective: This study aimed to evaluate the impact of neoadjuvant therapy on postoperative outcomes in patients undergoing RATS for NSCLC, focusing on operative time, conversion rates to open surgery, and postoperative complications. Methods: A retrospective cohort analysis was performed on patients who underwent RATS for NSCLC between February 2019 and August 2024. Propensity score matching was utilized to balance preoperative characteristics between the groups. The primary outcomes compared were operative time, conversion rates to open surgery, and postoperative complications, with statistical significance defined as p < 0.05. Results: A total of 253 patients were included in the analysis, of whom 23 received neoadjuvant therapy (either chemotherapy or chemoimmunotherapy) and 230 did not. The neoadjuvant group had significantly longer operative times (250 min vs. 221 min, p = 0.001) but there were no significant differences in conversion rates to open surgery (8.7% vs. 3.9%, p = 0.5). However, the neoadjuvant group showed a higher incidence of prolonged air leaks (>5 days) (39.13% vs. 35.21%, p < 0.001). Other parameters, such as hospital stay and chest drainage duration, showed no statistically significant differences between the groups (p = 0.860 and p = 0.760, respectively). Conclusions: These findings support the feasibility of robotic-assisted thoracic surgery following neoadjuvant therapy in NSCLC, suggesting that this approach may be safely integrated into clinical practice for selected patients. Further studies are needed to define patient selection criteria and optimize postoperative management, potentially guiding personalized treatment strategies in complex cases.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16233938</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Body mass index ; Cancer therapies ; Cardiac arrhythmia ; Chemotherapy ; Complications ; Emphysema ; Hemothorax ; Immunotherapy ; Infections ; Ischemia ; Lung cancer ; Non-small cell lung carcinoma ; Ostomy ; Patients ; Pneumothorax ; Postoperative ; Regression analysis ; Robotic surgery ; Robotics ; Small cell lung carcinoma ; Surgical outcomes ; Thoracic surgery ; Thorax ; Tumors</subject><ispartof>Cancers, 2024-11, Vol.16 (23), p.3938</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1098-1e06be357f9b8cd42e4c265ec193f7b009d7efb36a9209c9701d65cf1f8137283</cites><orcidid>0000-0001-5814-921X ; 0009-0005-8632-830X ; 0000-0002-9674-5554 ; 0000-0002-9511-9199 ; 0000-0002-3865-3184 ; 0000-0002-3789-2052 ; 0000-0002-5718-8900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Serratosa, Inés</creatorcontrib><creatorcontrib>Déniz, Carlos</creatorcontrib><creatorcontrib>Moreno, Camilo</creatorcontrib><creatorcontrib>Macia, Iván</creatorcontrib><creatorcontrib>Rivas, Francisco</creatorcontrib><creatorcontrib>Muñoz, Anna</creatorcontrib><creatorcontrib>Paradela, Marina</creatorcontrib><creatorcontrib>Nadal, Ernest</creatorcontrib><creatorcontrib>Mosteiro, Miguel</creatorcontrib><creatorcontrib>Padrones, Susana</creatorcontrib><creatorcontrib>García, Marta</creatorcontrib><creatorcontrib>Rodríguez-Martos, Tania</creatorcontrib><creatorcontrib>Marcè, Judith</creatorcontrib><creatorcontrib>Ojanguren, Amaia</creatorcontrib><title>Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes</title><title>Cancers</title><description>Background: Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its effect on postoperative outcomes following robotic-assisted thoracic surgery (RATS) is not fully characterized. Objective: This study aimed to evaluate the impact of neoadjuvant therapy on postoperative outcomes in patients undergoing RATS for NSCLC, focusing on operative time, conversion rates to open surgery, and postoperative complications. Methods: A retrospective cohort analysis was performed on patients who underwent RATS for NSCLC between February 2019 and August 2024. Propensity score matching was utilized to balance preoperative characteristics between the groups. The primary outcomes compared were operative time, conversion rates to open surgery, and postoperative complications, with statistical significance defined as p < 0.05. Results: A total of 253 patients were included in the analysis, of whom 23 received neoadjuvant therapy (either chemotherapy or chemoimmunotherapy) and 230 did not. The neoadjuvant group had significantly longer operative times (250 min vs. 221 min, p = 0.001) but there were no significant differences in conversion rates to open surgery (8.7% vs. 3.9%, p = 0.5). However, the neoadjuvant group showed a higher incidence of prolonged air leaks (>5 days) (39.13% vs. 35.21%, p < 0.001). Other parameters, such as hospital stay and chest drainage duration, showed no statistically significant differences between the groups (p = 0.860 and p = 0.760, respectively). Conclusions: These findings support the feasibility of robotic-assisted thoracic surgery following neoadjuvant therapy in NSCLC, suggesting that this approach may be safely integrated into clinical practice for selected patients. Further studies are needed to define patient selection criteria and optimize postoperative management, potentially guiding personalized treatment strategies in complex cases.</description><subject>Body mass index</subject><subject>Cancer therapies</subject><subject>Cardiac arrhythmia</subject><subject>Chemotherapy</subject><subject>Complications</subject><subject>Emphysema</subject><subject>Hemothorax</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Ischemia</subject><subject>Lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Ostomy</subject><subject>Patients</subject><subject>Pneumothorax</subject><subject>Postoperative</subject><subject>Regression analysis</subject><subject>Robotic surgery</subject><subject>Robotics</subject><subject>Small cell lung carcinoma</subject><subject>Surgical outcomes</subject><subject>Thoracic surgery</subject><subject>Thorax</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkM1Lw0AQxRdRsNSevS54ju5Hupv1JqV-QLGgFY9hs5m0W5Js3d0U89-b2h7EuczM4zFv-CF0Tckt54rcGd0a8IEKNqw8O0MjRiRLhFDp-Z_5Ek1C2JKhOKdSyBHavILT5bbb6zbi1Qa83vXYtvjNFS5agxddu8bvnV-D7-_xvIa9jvYkWaNrPHPNroZvG3v8aePGdfFX8q6x4WBcdtG4BsIVuqh0HWBy6mP08ThfzZ6TxfLpZfawSAwlKksoEFEAn8pKFZkpUwapYWIKhipeyYIQVUqoCi60YkQZJQktxdRUtMoolyzjY3RzvDu88NVBiPnWdb4dInNO04EVy4gaXHdHl_EuBA9VvvO20b7PKckPRPN_RPkP_XVrtQ</recordid><startdate>20241125</startdate><enddate>20241125</enddate><creator>Serratosa, Inés</creator><creator>Déniz, Carlos</creator><creator>Moreno, Camilo</creator><creator>Macia, Iván</creator><creator>Rivas, Francisco</creator><creator>Muñoz, Anna</creator><creator>Paradela, Marina</creator><creator>Nadal, Ernest</creator><creator>Mosteiro, Miguel</creator><creator>Padrones, Susana</creator><creator>García, Marta</creator><creator>Rodríguez-Martos, Tania</creator><creator>Marcè, Judith</creator><creator>Ojanguren, Amaia</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0001-5814-921X</orcidid><orcidid>https://orcid.org/0009-0005-8632-830X</orcidid><orcidid>https://orcid.org/0000-0002-9674-5554</orcidid><orcidid>https://orcid.org/0000-0002-9511-9199</orcidid><orcidid>https://orcid.org/0000-0002-3865-3184</orcidid><orcidid>https://orcid.org/0000-0002-3789-2052</orcidid><orcidid>https://orcid.org/0000-0002-5718-8900</orcidid></search><sort><creationdate>20241125</creationdate><title>Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes</title><author>Serratosa, Inés ; Déniz, Carlos ; Moreno, Camilo ; Macia, Iván ; Rivas, Francisco ; Muñoz, Anna ; Paradela, Marina ; Nadal, Ernest ; Mosteiro, Miguel ; Padrones, Susana ; García, Marta ; Rodríguez-Martos, Tania ; Marcè, Judith ; Ojanguren, Amaia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1098-1e06be357f9b8cd42e4c265ec193f7b009d7efb36a9209c9701d65cf1f8137283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Body mass index</topic><topic>Cancer therapies</topic><topic>Cardiac arrhythmia</topic><topic>Chemotherapy</topic><topic>Complications</topic><topic>Emphysema</topic><topic>Hemothorax</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Ischemia</topic><topic>Lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Ostomy</topic><topic>Patients</topic><topic>Pneumothorax</topic><topic>Postoperative</topic><topic>Regression analysis</topic><topic>Robotic surgery</topic><topic>Robotics</topic><topic>Small cell lung carcinoma</topic><topic>Surgical outcomes</topic><topic>Thoracic surgery</topic><topic>Thorax</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serratosa, Inés</creatorcontrib><creatorcontrib>Déniz, Carlos</creatorcontrib><creatorcontrib>Moreno, Camilo</creatorcontrib><creatorcontrib>Macia, Iván</creatorcontrib><creatorcontrib>Rivas, Francisco</creatorcontrib><creatorcontrib>Muñoz, Anna</creatorcontrib><creatorcontrib>Paradela, Marina</creatorcontrib><creatorcontrib>Nadal, Ernest</creatorcontrib><creatorcontrib>Mosteiro, Miguel</creatorcontrib><creatorcontrib>Padrones, Susana</creatorcontrib><creatorcontrib>García, Marta</creatorcontrib><creatorcontrib>Rodríguez-Martos, Tania</creatorcontrib><creatorcontrib>Marcè, Judith</creatorcontrib><creatorcontrib>Ojanguren, Amaia</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serratosa, Inés</au><au>Déniz, Carlos</au><au>Moreno, Camilo</au><au>Macia, Iván</au><au>Rivas, Francisco</au><au>Muñoz, Anna</au><au>Paradela, Marina</au><au>Nadal, Ernest</au><au>Mosteiro, Miguel</au><au>Padrones, Susana</au><au>García, Marta</au><au>Rodríguez-Martos, Tania</au><au>Marcè, Judith</au><au>Ojanguren, Amaia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes</atitle><jtitle>Cancers</jtitle><date>2024-11-25</date><risdate>2024</risdate><volume>16</volume><issue>23</issue><spage>3938</spage><pages>3938-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Background: Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its effect on postoperative outcomes following robotic-assisted thoracic surgery (RATS) is not fully characterized. Objective: This study aimed to evaluate the impact of neoadjuvant therapy on postoperative outcomes in patients undergoing RATS for NSCLC, focusing on operative time, conversion rates to open surgery, and postoperative complications. Methods: A retrospective cohort analysis was performed on patients who underwent RATS for NSCLC between February 2019 and August 2024. Propensity score matching was utilized to balance preoperative characteristics between the groups. The primary outcomes compared were operative time, conversion rates to open surgery, and postoperative complications, with statistical significance defined as p < 0.05. Results: A total of 253 patients were included in the analysis, of whom 23 received neoadjuvant therapy (either chemotherapy or chemoimmunotherapy) and 230 did not. The neoadjuvant group had significantly longer operative times (250 min vs. 221 min, p = 0.001) but there were no significant differences in conversion rates to open surgery (8.7% vs. 3.9%, p = 0.5). However, the neoadjuvant group showed a higher incidence of prolonged air leaks (>5 days) (39.13% vs. 35.21%, p < 0.001). Other parameters, such as hospital stay and chest drainage duration, showed no statistically significant differences between the groups (p = 0.860 and p = 0.760, respectively). Conclusions: These findings support the feasibility of robotic-assisted thoracic surgery following neoadjuvant therapy in NSCLC, suggesting that this approach may be safely integrated into clinical practice for selected patients. Further studies are needed to define patient selection criteria and optimize postoperative management, potentially guiding personalized treatment strategies in complex cases.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/cancers16233938</doi><orcidid>https://orcid.org/0000-0001-5814-921X</orcidid><orcidid>https://orcid.org/0009-0005-8632-830X</orcidid><orcidid>https://orcid.org/0000-0002-9674-5554</orcidid><orcidid>https://orcid.org/0000-0002-9511-9199</orcidid><orcidid>https://orcid.org/0000-0002-3865-3184</orcidid><orcidid>https://orcid.org/0000-0002-3789-2052</orcidid><orcidid>https://orcid.org/0000-0002-5718-8900</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2024-11, Vol.16 (23), p.3938 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_proquest_journals_3143902809 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Body mass index Cancer therapies Cardiac arrhythmia Chemotherapy Complications Emphysema Hemothorax Immunotherapy Infections Ischemia Lung cancer Non-small cell lung carcinoma Ostomy Patients Pneumothorax Postoperative Regression analysis Robotic surgery Robotics Small cell lung carcinoma Surgical outcomes Thoracic surgery Thorax Tumors |
title | Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T18%3A59%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20Therapy%20in%20Robotic%20Lung%20Surgery:%20Elevating%20Surgical%20Complexity%20Without%20Compromising%20Outcomes&rft.jtitle=Cancers&rft.au=Serratosa,%20In%C3%A9s&rft.date=2024-11-25&rft.volume=16&rft.issue=23&rft.spage=3938&rft.pages=3938-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16233938&rft_dat=%3Cproquest_cross%3E3143902809%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3143902809&rft_id=info:pmid/&rfr_iscdi=true |